OTCMKTS:RLMD
Relmada Therapeutics, Inc. Stock News
$3.34
-0.150 (-4.30%)
At Close: May 17, 2024
LOS ANGELES, CA / ACCESSWIRE / May 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeuti
LOS ANGELES, CA / ACCESSWIRE / May 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeuti
LOS ANGELES, CA / ACCESSWIRE / May 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeuti
LOS ANGELES, CA / ACCESSWIRE / May 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeuti
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
04:05pm, Wednesday, 08'th May 2024
CORAL GABLES, Fla., May 8, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a
Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
07:30am, Monday, 06'th May 2024
CORAL GABLES, Fla. , May 6, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced
Relmada Therapeutics: Run Up Into Results May Resume Following This Drop
06:57pm, Thursday, 21'st Mar 2024
RLMD plans to report results from the phase 3 Reliance II study of REL-1017, as an adjunctive treatment for major depressive disorder, in H2 2024. The current timeline for completion of enrolment in R
Relmada Therapeutics, Inc. (RLMD) Q4 2023 Earnings Call Transcript
07:08pm, Tuesday, 19'th Mar 2024
Relmada Therapeutics, Inc. (RLMD) Q4 2023 Earnings Call Transcript
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
04:15pm, Tuesday, 19'th Mar 2024
CORAL GABLES, Fla. , March 19, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provid
CORAL GABLES, Fla. , March 12, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announc
Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
07:30am, Tuesday, 05'th Mar 2024
CORAL GABLES, Fla. , March 5, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announce
Relmada Therapeutics Provides Corporate Update
07:30am, Thursday, 04'th Jan 2024
Company Well-Positioned for a Pivotal 2024 with Multiple Key Clinical Development Milestones Anticipated Relmada's Strong Balance Sheet to Support the Company Through All of 2024's Expected Critical C
Relmada Therapeutics, Inc. (RLMD) Q3 2023 Earnings Call Transcript
02:56am, Thursday, 09'th Nov 2023
Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q3 2023 Results Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Tim McCarthy - Investor Relations, Advisors Sergio Traversa - Chief
Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023
07:30am, Friday, 03'rd Nov 2023
CORAL GABLES, Fla. , Nov. 3, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced
Relmada And REL-1017: Intriguing Underlying Efficacy In MDD Ahead Of Eventful 2024
07:50pm, Friday, 13'th Oct 2023
Phase 3 trial failures were due to abnormally high placebo responses driven by poor trial design, enrollment, and oversight. REL-1017's underlying efficacy appears robust, consistently reporting treat